ObsEva (OBSV) Stock Price, News & Analysis

Company Overview

ObsEva SA was a biopharmaceutical company focused on developing and commercializing therapies for women’s health. Founded in Geneva, Switzerland, the company concentrated on reproductive-health conditions, including uterine fibroids, endometriosis and infertility.

Its principal product candidate was linzagolix, an oral gonadotropin-releasing hormone antagonist developed for the treatment of uterine fibroids and endometriosis-associated symptoms. Linzagolix received marketing authorization in the European Union under the brand name Yselty for the treatment of moderate-to-severe symptoms associated with uterine fibroids in adult women of reproductive age. ObsEva also evaluated other reproductive-health drug candidates during its development history, including treatments intended to support embryo implantation and fertility procedures.

ObsEva operated internationally, with corporate roots in Switzerland and clinical-development and commercial activities directed toward markets in Europe and the United States. The company later encountered significant financial difficulties and entered insolvency proceedings, and its Nasdaq listing was subsequently discontinued. Commercial rights to Yselty have been associated with Theramex in certain markets. ObsEva was historically led by executives including co-founder and Chief Executive Officer Ernest Loumaye.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 50 shs
• Average Volume: 8.94 million shs
• Market Capitalization: $7.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/04/2021
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OBSV
• CIK: 1685316
• Web: www.obseva.com
• Phone: (122) 552-3840
• Fax: N/A
• Employees: 50
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -416.36%
• Return on Assets: -92.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 77,971,000
• Free Float: 66,743,000
• Market Cap: $7.94 million
• Optionable: Not Optionable
• Beta: 0.68